An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Latest Information Update: 14 Feb 2024
At a glance
- Drugs Fruquintinib (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Endometrial cancer; Male breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
- 08 Feb 2024 Planned End Date changed from 1 Mar 2024 to 1 Nov 2024.
- 08 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jul 2024.
- 08 Feb 2024 Status changed from recruiting to active, no longer recruiting.